A post hoc ReFocus analysis found prior immune checkpoint inhibitor exposure raised the risk of mucocutaneous AEs with lirafugratinib.
|Videos|June 13, 2011
ASCO: Recent Advances in Using a “Systems Approach” in Oncology
Author(s)John Mendelsohn, MD
John Mendelsohn, president of the MD Anderson Cancer Center, discusses with ONCOLOGY the recent advances in using a “systems approach” in oncology and how he believes this will affect outcomes in the future.
Advertisement
John Mendelsohn, president of the MD Anderson Cancer Center, discusses with ONCOLOGY the recent advances in using a “systems approach” in oncology and how he believes this will affect outcomes in the future.
Advertisement
Related to this article
Data from the real-world CEMI-LUNG evaluating cemiplimab in advanced NSCLC were consistent with reports from the EMPOWER-Lung1 study.
A cisplatin-free pembrolizumab regimen yielded 65.1% laryngectomy-free survival rate at 2 years in SMART-KEY, missing significance vs historical controls.
Risvutatug rezetecan cut the risk of progression or death by 67% vs gemcitabine/docetaxel in heavily pretreated R/R osteosarcoma in ARTEMIS-011.
Two-year MANEUVER data show durable, deepening responses and sustained gains in pain, stiffness, and function with pimicotinib in TGCT.
At Big Ten CRC, Patricia A. Robinson, MD, discussed institutional and cooperative group strategies that have improved representation in oncology clinical trials.
Biomarker and preclinical data support SEZ6 as a potential therapeutic target in small cell lung cancer management.
Jesus Corral Jaime, MD, reviews real-world survival and response data for cemiplimab monotherapy from the CEMI-LUNG study.
Advertisement
Advertisement
Trending on CancerNetwork
1
Sac-TMT Improves Survival vs Chemotherapy in Pretreated Endometrial Cancer
2
Cemiplimab Shows Real-World Efficacy in Advanced NSCLC Study
3
Calderasib Regimen Shows Meaningful Responses in Frontline KRAS G12C+ NSCLC
4
Pembrolizumab Improves PFS Over Chemo in dMMR Endometrial Cancer
5